Zonisamide, reducing action potential firing in NIPA2‐knockout mice, is probably a potential treatment for NIPA2 mutation‐induced epilepsy, which may provide a basis for the development of new treatment strategies for epilepsy. The gene discussed is NIPA2; the disease is epilepsy.